- ICH GCP
- 欧盟临床试验注册处
最新试用
EudraCT Number: 2004-000326-70 | Sponsor Protocol Number: R076477-SCH-302/702 | Start Date: 2004-08-11 | ||||||
Sponsor Name: Janssen-Cilag, Johnson & Johnson spol. s.r.o. | ||||||||
Full Title: A Randomized, 6-Week Double-Blind, Placebo-Controlled Study With an Optional 24-Week Open-Label Extension to Evaluate the Safety and Tolerability of Flexible Doses of Extended Release OROS® Paliper... | ||||||||
Medical condition: Schizophrenia | ||||||||
|
||||||||
Population Age: Elderly | Gender: Male, Female | |||||||
Trial protocol: CZ (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-000798-71 | Sponsor Protocol Number: 1 | Start Date: 2004-08-11 | ||||||
Sponsor Name: Imperial College London | ||||||||
Full Title: Efficacy of Levetiracetam in Pendular Nystagmus: A Randomized, Double-blind, Placebo-controlled trial with crossover | ||||||||
Medical condition: Pendular Nystagmus from various etiology | ||||||||
|
||||||||
Population Age: Adults | Gender: Male, Female | |||||||
Trial protocol: GB (Prematurely Ended) | ||||||||
Trial results: View results |
EudraCT Number: 2004-000487-27 | Sponsor Protocol Number: 0663-806 | Start Date: 2004-08-10 | |||||||||||
Sponsor Name: Merck Sharp & Dohme (Sweden) AB | |||||||||||||
Full Title: A Double-Blind, Parallel-Group, 4-week Trial to Assess the Efficacy and Safety of Etoricoxib 60mg and Diclofenac 150mg in Patients with Chronic Low Back Pain | |||||||||||||
Medical condition: Chronic Low Back Pain | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) HU (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000414-39 | Sponsor Protocol Number: BUP4203 | Start Date: 2004-08-10 | |||||||||||
Sponsor Name: Mundipharma OY | |||||||||||||
Full Title: A randomised, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the long-term efficacy and safety of Norspan® versus placebo Norspan in subjects with chronic, moderate... | |||||||||||||
Medical condition: Chronic, moderate to severe osteoarthritis pain of the hip and/or knee. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000589-11 | Sponsor Protocol Number: F1D-MC-HGKR | Start Date: 2004-08-10 | ||||||
Sponsor Name: ELI LILLY and COMPANY | ||||||||
Full Title: Protocol F1D-MC-HGKR. Olanzapine Plus Carbamazepine Versus Carbamazepine Alone in the Treatment of Manic or Mixed Episodes Associated with Bipolar I Disorder | ||||||||
Medical condition: Manic or Mixed Episodes Associated with Bipolar I Disorder | ||||||||
|
||||||||
Population Age: Adults | Gender: Male, Female | |||||||
Trial protocol: HU (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-000476-13 | Sponsor Protocol Number: SP738 | Start Date: 2004-08-10 | ||||||
Sponsor Name: Schwarz Biosciences GmbH | ||||||||
Full Title: LONG-TERM OPEN-LABEL EXTENSION TRIAL FOR SUBJECTS COMPLETING THE PHASE 3 TRIAL OF FESOTERODINE (SP583) FOR THE TREATMENT OF OVERACTIVE BLADDER SYNDROME | ||||||||
Medical condition: overactive bladder | ||||||||
|
||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||
Trial protocol: ES (Completed) IT (Completed) | ||||||||
Trial results: View results |
EudraCT Number: 2004-000025-29 | Sponsor Protocol Number: CQAB149B2205 | Start Date: 2004-08-10 | |||||||||||
Sponsor Name: Novartis Sweden AB | |||||||||||||
Full Title: Full title of the trial : A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of ... | |||||||||||||
Medical condition: Moderate to severe Chronic Obstructive Pulmonary Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) DK (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001100-12 | Sponsor Protocol Number: 1198.022 | Start Date: 2004-08-09 | |||||||||||
Sponsor Name: Boehringer Ingelheim Pharma Ges mbH | |||||||||||||
Full Title: A multi-centre, double-blind, parallel-group, randomised, placebo-controlled study to investigate the safety and tolerability of 0.25, 0.5 and 1.0 mg NS 2330 orally and once daily during a 14-week ... | |||||||||||||
Medical condition: Mild to moderate dementia of the Alzheimer's type | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000039-27 | Sponsor Protocol Number: MI-CP110 | Start Date: 2004-08-09 | |||||||||||
Sponsor Name: MedImmune, Inc. | |||||||||||||
Full Title: A pivotal phase 3 study of MEDI-524 (Numax), an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody, for the prophylaxis of serious RSV disease in high-risk children. | |||||||||||||
Medical condition: Serious respiratory syncytial virus (RSV) disease | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) HU (Completed) CZ (Completed) DK (Completed) IS (Completed) AT (Completed) IT (Completed) GB (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2004-000866-11 | Sponsor Protocol Number: 7164-L-01 | Start Date: 2004-08-06 | |||||||||||
Sponsor Name: ZAMBON GROUP | |||||||||||||
Full Title: A multicenter, randomized, parallel group, controlled, double-blind study to evaluate efficacy and safety of pholcodine as antitussive agent vs dextrometorphan in non-productive cough | |||||||||||||
Medical condition: Symptomatic treatment of non productive cough | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |